BRIEF

on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)

Crossing thresholds for GENSIGHT BIOLOGICS SA

On May 22, 2024, GENSIGHT BIOLOGICS SA received a threshold crossing declaration from the American company Armistice Capital, LLC. The latter, acting on behalf of the Armistice Capital Master Fund Ltd., crossed the thresholds of 5% of the company's capital and voting rights on May 9, 2024.

On this date, Armistice Capital held 6,329,113 GENSIGHT BIOLOGICS SA shares, representing 6.21% of the capital and voting rights. This crossing results from the subscription to a capital increase of the company.

As of May 22, 2024, Armistice Capital reported holding 6,292,000 GENSIGHT BIOLOGICS SA shares, or 6.18% of the capital and voting rights. In addition, it has 6,329,113 share subscription warrants exercisable until November 9, 2026, offering the right to as many shares at a unit price of €0.45.

R. P.

Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.

Click here to consult the press release on which this article is based

See all GENSIGHT BIOLOGICS S.A. news